May 12, 2013 by Dave Williamson1 Biotech's Surprise Dilution DecodedIsis Pharmaceuticals gives biotech investors a painful reminder that dilution can come when they least expect it.
May 11, 2013 by Dave WilliamsonDendreon: Picking Through the CarnageFirst-quarter results for the prostate cancer drug maker were even uglier than anticipated.
May 11, 2013 by Dave WilliamsonDeal Discussions Distract From Disappointing Obesity Drug SalesMaking sense of Vivus' first quarter results for investors.
May 8, 2013 by Dave WilliamsonAre Insurers Exaggerating Medicare Advantage Cuts?JPMorgan thinks the Obamacare handwringing is overdone.
May 8, 2013 by Dave WilliamsonA "Me Too" FDA BreakthroughWhy AbbVie's Food and Drug Administration breakthrough designation isn't a big deal.
May 8, 2013 by Dave WilliamsonThe Potential Death Knell of a Multibillion-Dollar IndustryPfizer tries to boost sales by eliminating a public health risk.
May 7, 2013 by Dave WilliamsonDoes Ariad's Leukemia Drug Have Hidden Potential?Ariad's Iclusig launch is beating Wall Street, but should investors join the ride?
May 7, 2013 by Dave WilliamsonPicking Up the Pieces of Another Alzheimer's FailureWhat's next for Baxter's Gammagard and the future of Alzheimer's treatments?
May 7, 2013 by Dave WilliamsonWhat Gov. Christie's Secret Weight-Loss Surgery Means for InvestorsCan investors profit from the governor's gastric band surgery?
May 6, 2013 by Dave WilliamsonThis Health-Care Revolution Is Only Just BeginningAnd one stock investors looking to profit from this revolution need to watch
May 6, 2013 by Dave WilliamsonThis Week's Must-Watch Stock: DendreonDendreon has set expectations low for the quarter, can they surprise investors?
May 5, 2013 by Dave WilliamsonGilead's Game-Changer Delivers the GoodsIt looks as if Gilead's single daily pill will be the standard of care for curing hepatitis C.
May 5, 2013 by Dave WilliamsonAre Obesity Drugs a Lost Cause in Europe?Vivus has been twice rejected in Europe, and now Arena pulls its drug from the approval process.
May 2, 2013 by Dave WilliamsonWhy Investors Shouldn't Worry About Sanofi's Poor QuarterIt's all about guidance, drug launches, and the pipeline for the European big pharma
May 2, 2013 by Dave WilliamsonAn FDA Advisory Committee Kill ShotShares plunge 50% as Aveo Pharmaceutical's kidney cancer drug gets a 13-1 "no" vote.
Apr 30, 2013 by Dave WilliamsonThe FDA Firing Squad Takes AimFDA advisory committee briefing documents range from damaging to devastating.
Apr 30, 2013 by Dave WilliamsonThe Great Acquirer Strikes AgainBut is this proposed merger of equals a mistake?
Apr 30, 2013 by Dave WilliamsonAetna Succeeding As Obamacare Looms2013 looks bright for the big insurer.
Apr 30, 2013 by Dave WilliamsonWhy Pfizer's Bad Outlook Doesn't MatterA short-term stumble isn't the real story. Focus on the pipeline.
Apr 29, 2013 by Dave WilliamsonEurope Hands Down 2 Critical Drug DecisionsMedivation's Xtandi get a thumbs up, while Pfizer's Xeljanz gets a thumbs down.
